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Background: Two cytidine analogues, gemcitabine and cytosine arabinoside (AraC), are widely used in the
treatment of a variety of cancers with a large individual variation in response. To identify potential genetic
biomarkers associated with response to these two drugs, we used a human lymphoblastoid cell line (LCL) model
system with extensive genomic data, including 1.3 million SNPs and 54,000 basal expression probesets to perform
genome-wide association studies (GWAS) with gemcitabine and AraC IC50 values.
Results: We identified 11 and 27 SNP loci significantly associated with gemcitabine and AraC IC50 values,
respectively. Eleven candidate genes were functionally validated using siRNA knockdown approach in multiple
cancer cell lines. We also characterized the potential mechanisms of genes by determining their influence on the
activity of 10 cancer-related signaling pathways using reporter gene assays. Most SNPs regulated gene expression in
a trans manner, except 7 SNPs in the PIGB gene that were significantly associated with both the expression of PIGB
and gemcitabine cytotoxicity.
Conclusion: These results suggest that genetic variation might contribute to drug response via either cis- or
trans- regulation of gene expression. GWAS analysis followed by functional pharmacogenomics studies might help
identify novel biomarkers contributing to variation in response to these two drugs and enhance our understanding
of underlying mechanisms of drug action.
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Both gemcitabine and AraC are widely used in the treat-
ment of a variety of cancers and both display wide individ-
ual variation in drug response [1-6]. Pharmacogenomic
studies have the potential to provide insight into mecha-
nisms underlying individual variation in response to these
two drugs [7-11]. Many previous pharmacogenetic studies
focused on the bioactivation and metabolism pathways for
cytidine analogues [12,13]. For example, SNPs in genes
encoding ribonucleotide reductase (RRM1) and cytidine* Correspondence: wang.liewei@mayo.edu
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reproduction in any medium, provided the ordeaminase (CDA) were found to be associated with gemci-
tabine chemosensitivity in the NCI-60 cell lines or with
active gemcitabine metabolite plasma levels [14-16]. Those
findings provided the initial evidence that genetic variation
might contribute to variation in cytidine analogue re-
sponse. We previously used the “Human Variation Panel”,
a genomic data-rich lymphoblastoid cell line model sys-
tem, to identify markers that might contribute to variation
in response to these two cytidine analogues [17,18]. These
cell lines have proven to be a powerful tool for both the
identification of pharmacogenomic hypotheses and for the
pursuit of hypotheses from the clinical GWAS [19-21].
However, the earlier studies were performed with less
dense SNP coverage, in the present study, we expanded
our previous 550 K SNP data to include a total of 1.3his is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SNP genotyping platforms in an attempt to identify add-
itional genes or SNPs that might be associated with drug
response. To follow-up the candidates, we performed
functional studies using tumor cell lines in an attempt to
determine possible underlying mechanisms that might
help us to better understand mechanisms of action for
these two drugs. The results of the comprehensive series
of experiments described subsequently resulted in the
identification of several novel SNPs and genes associated
with gemcitabine and AraC drug response in these cell
lines. These results could be tested in future clinical stud-
ies to determine whether they might help predict response
to gemcitabine and AraC.
Methods
Cell lines
One hundred and seventy four human lymphoblastoid
cell lines from 60 Caucasian-American (CA), 54 African-
American (AA) and 60 Han Chinese-American (HCA)
(sample sets HD100CAU, HD100AA, and HD100CHI)
subjects were purchased from the Coriell Cell Repository
(Camden, NJ). All of these cell lines had been obtained
and anonymized by the National Institute of General
Medical Sciences prior to deposit, and all subjects had
provided written consent for the use of their DNA and
cells for experimental purposes. Human SU86 pancreatic
cancer cell lines were a gift from Dr. Daniel D. Billadeau
(Department of Immunology and Division of Oncology
Research, Mayo Clinic College of Medicine). Human
breast cancer MDA-MB-231 and leukemia BDCM and
THP-1 cell lines were purchased from the American
Type Culture Collection (ATCC) (Manassas, VA) and were
cultured in DMEM with 1% L-glutamine (Mediatech) sup-
plemented with 10% FBS (Mediatech). Other cell lines were
maintained in RPMI medium 1640 with 1% L-glutamine
(Mediatech) supplemented with 10% FBS (Mediatech).
Drugs and cell proliferation assays
Gemcitabine was provided by Eli Lilly (Indianapolis, IN).
AraC was purchased from Sigma-Aldrich (St. Louis,
MO). Cytotoxicity assays with the lymphoblastoid and
tumor cell lines were performed with the CellTiter 96W
AQueous Non-Radioactive Cell Proliferation Assay (Promega
Corporation, Madison, WI) as previously described [17].
IC50 values were calculated using a three or four param-
eter logistic model with the R package “drc” (http://cran.
r-project.org/web/packages/drc/drc.pdf), as described pre-
viously [18].
SNP genotyping
In order to validate the imputation results, six top imputed
SNPs (rs10447475, rs4621668, rs11215400, rs10926784,
rs3196512 and rs7762319) were selected for genotypingusing Applied Biosystems TaqMan technology (Life
Technologies, Grand Island, NY). One SNP (rs7762319)
was not genotyped because the assay failed functional
test, and four of the remaining five SNPs were success-
fully genotyped. Among these four SNPs, rs11215400
was a pre-designed assay, while the remaining three
SNPs (rs10447475, rs4621668 and rs10926784) were
customized assays designed with Custom TaqManW
Assay Design Tool (Life Technologies, Grand Island,
NY). Primer and probe sequences for these assays are
available upon request. PCR protocols were followed
according to the manufacturer’s guidelines for the 384-
well format. PCR amplifications were performed using
Applied BiosystemsW TaqManW Genotyping Master
Mix with an Applied BiosystemsW VeritiW 384-Well
Thermal Cycler (Life Technologies, Grand Island, NY), and
PCR products were analyzed on an Applied Biosystems
7900HT [22].
Transient transfection and RNA interference
Specific siGENOME siRNA SMARTpoolW reagents against
a given gene, as well as a negative control, siGENOME
Non-Targeting siRNA Pool #2, were purchased from Dhar-
macon Inc. (Lafayette, CO). Human pancreatic cancer
SU86 and breast cancer MDA-MB-231 cell lines were used
to perform the siRNA knockdown studies. The lipofecta-
mine RNAiMAX transfection reagent (Invitrogen, Carlsbad,
CA) was used for siRNA reverse or forward transfection.
Specifically, cells were seeded into 96-well plates and were
mixed with siRNA-complex consisting of 20–50 nM of spe-
cific siGENOME siRNA SMARTpool or non-targeting
negative control (Dharmacon) and the lipofectamine RNAi-
MAX transfection reagent. The human leukemia cell lines,
BDCM and THP-1, were transfected with electroporation
using the Nucleofector System with 500 nM of specific or
negative siRNA (Lonza Inc., Basel, Switzerland).
Quantitative reverse transcription-PCR (QRT-PCR)
Total RNA was isolated from cultured cells with the
Qiagen RNeasy kit (QIAGEN Inc. Valencia, CA), followed
by QRT-PCR performed with the 1-step, Brilliant SYBR
Green QRT-PCR master mix kit (Stratagene, La Jolla,
CA). Specifically, primers purchased from Qiagen were used
to perform QRT-PCR with the Stratagene Mx3005P™ Real-
Time PCR detection system (Stratagene). All experiments
were performed in triplicate with β-actin as an internal con-
trol. Reverse transcribed Universal Human reference RNA
(Stratagene) was used to generate a standard curve. Control
reactions lacked RNA template.
Caspase-3/7 activity assay
Caspase-3/7 activity was measured with the Caspase-GloW3/
7 Assay kit (Promega). Specifically, siRNA-transfected cells
(100 μl) were seeded overnight into 96-well plates at a
Figure 1 GWAS findings. (A). Manhattan plot of 1.3 million SNPs with gemcitabine IC50 values. (B). Manhattan plot of 1.3 million SNPs with
gemcitabine IC50 values. SNPs are plotted on the x-axis based on their chromosomal locations. P values of 10-4 are highlighted with a red line.
Li et al. BMC Genomics 2014, 15:93 Page 3 of 22
http://www.biomedcentral.com/1471-2164/15/93density of 10,000 cells per well and were then treated with
DMSO or increasing concentrations of gemcitabine or AraC
for 48 h. 100 μL of Caspase-GloW 3/7 Reagent was then
added to each well, and the cells were incubated at room
temperature for 1 h, followed by the measurement of lumi-
nescence with a Safire2 microplate reader (Tecan Trading
AG, Switzerland). The luminescent signal was proportional
to caspase-3/7 activity and was used as a measure of apop-
tosis. Wells containing only culture medium were used as
controls.Cancer cignal finder 10-pathway reporter array
The Cignal Finder Arrays consist of 10 dual-luciferase
reporter assays for ten cancer-related signaling path-
ways. Each reporter construct is a mixture of an indu-
cible transcription factor (TF) responsive firefly luciferase
reporter and a constitutively expressing Renilla con-
struct at a ratio of 40:1, respectively (SABioscience Co.,
Frederick, MD). Specifically, cells were reversely trans-
fected with 30 nM of specific siRNA pools in 96-well
plates using Lipofectamine RNAiMAX reagent (Invitrogen)
Table 1 The top 11 loci for Gemcitabine (A) and the top 27 loci for AraC (B) that were associated with drug
response-IC50 values
Top SNP rsID Lowest R Lowest P Nearby gene Chr Position MAF Region Number of SNPs in each locus
(A) Gemcitabine
rs10513968 −0.382 1.04E-06 DOK6 18 65434121 0.445 Intron 9
rs7719624 −0.370 4.22E-06 TGFBI 5 135405465 0.448 Intron 28
rs2274870 0.362 4.33E-06 NIPSNAP3A 9 106555035 0.371 Coding 7
rs316838 −0.345 1.21E-05 PLD5* 1 240387283 0.093 Intron 12
rs2638094 −0.339 1.72E-05 ZNF215* 11 6938064 0.679 Flanking_3UTR 5
rs2290344 0.339 1.75E-05 PIGB 15 53407088 0.253 Coding 9
rs3129890 0.332 2.67E-05 HLA-DRA* 6 32522251 0.340 Flanking_3UTR 23
rs2928445 −0.331 2.76E-05 IPMK 10 58816782 0.267 Flanking_3UTR 23
rs4392391 −0.318 5.78E-05 C3orf23 3 44247970 0.419 Downstream 15
rs12522395 0.318 6.58E-05 MASS1* 5 90246274 0.215 Intron 4
rs13171512 −0.313 7.857E-05 PIK3R1 5 68000787 0.462 Flanking_3UTR 4
(B) AraC
rs10495285 0.393 4.13E-07 KIAA0133 (URB2) 1 227871618 0.171 Downstream 2
rs1450679 0.389 5.20E-07 SMC2L1 9 106066633 0.098 Flanking_3UTR 8
rs6128386 0.375 1.38E-06 LOC149773 20 56626955 0.466 Upstream 4
rs2172820 −0.373 1.63E-06 TUSC3 8 15370039 0.256 Flanking_5UTR 13
rs2857891 −0.372 1.75E-06 ZNF215* 11 6919533 0.101 Intron 6
rs9512755 −0.361 3.67E-06 LNX2 13 27056229 0.055 Flanking_5UTR 4
rs888468 −0.356 5.08E-06 FGF6 12 4403640 0.184 Flanking_3UTR 5
rs2653165 −0.347 9.28E-06 PLD5* 1 240432905 0.207 Intron 7
rs11215416 −0.346 9.57E-06 IGSF4 11 114582537 0.147 Intron 7
rs10060641 0.335 1.90E-05 MASS1* 5 90249006 0.216 Intron 7
rs5989586 0.336 1.94E-05 HDHD1A 23 6757306 0.457 Flanking_3UTR 8
rs216465 −0.330 2.76E-05 GOSR1 17 25880801 0.494 Flanking_3UTR 12
rs856548 −0.326 3.29E-05 TNS3 7 46730993 0.296 Flanking_3UTR 8
rs6689258 0.325 3.40E-05 GPR137B 1 234362702 0.267 Flanking_5UTR 2
rs3794794 −0.325 3.61E-05 CPD 17 25744867 0.477 Intron 10
rs7192 0.322 4.10E-05 HLA-DRA* 6 32519624 0.371 Coding 11
rs4572738 0.322 4.45E-05 CAST1 3 55799452 0.321 Intron 8
rs1433446 0.319 5.05E-05 TMEM83 15 85351874 0.109 Flanking_5UTR 5
rs300962 0.320 5.47E-05 LOC51334 5 119909842 0.269 Intron 15
rs6441911 0.315 6.20E-05 RIS1 3 45322523 0.055 Flanking_5UTR 6
rs1159388 0.314 6.61E-05 DCAMKL1 13 35544706 0.172 Intron 11
rs718979 0.313 6.82E-05 UBE3A 15 23325370 0.394 Flanking_5UTR 6
rs1955412 0.309 8.74E-05 FLRT2 14 85082547 0.21 Intron 11
Each locus contained at least 2 SNPs within 50 kb with P values <10-4. R values represent correlation coefficients for the association. Number of SNPs indicates the
number of significantly associated SNPs in the locus. rsID indicates the most significant SNP associated with drug cytotoxicity in the locus. * = common to both
gemcitabine and AraC.
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porter construct. Forty-eight h after the transfection, a
dual-luciferase assay was performed with the Dual-
Luciferase Reporter Assay System (Promega) in a Safire2
microplate reader (Tecan).Electrophoresis mobility shift assays (EMSA)
Based on the genome-wide association results, we per-
formed EMSA for SNPs in potential regulatory regions
of genes that were associated with the measured pheno-
types. Specifically, double-strand probes were 5′-end
Table 2 Integrated analyses for drug response for either (A) Gemcitabine or (B) AraC
SNP Probe set GWAS





















rs316871 PLD5 0.097 1 240409507 Intron 225532_at CABLES1 18 -0.326 4.14E–05 -0.242 6.54E–05 0.347 3.12E–06
rs316823 PLD5 0.093 1 240422651 Intron 225532_at CABLES1 18 -0.288 2.88E–04 -0.257 2.05E–05 0.347 3.12E–06
rs402098 PLD5 0.093 1 240430321 Intron 225532_at CABLES1 18 -0.288 2.88E–04 -0.257 2.05E–05 0.347 3.12E–06
rs427498 PLD5 0.087 1 240424078 Intron 225532_at CABLES1 18 -0.280 4.43E–04 -0.256 2.28E–05 0.347 3.12E–06
rs316823 PLD5 0.093 1 240422651 Intron 225531_at CABLES1 18 -0.288 2.88E–04 -0.239 7.69E–05 0.321 1.72E–05
rs402098 PLD5 0.093 1 240430321 Intron 225531_at CABLES1 18 -0.288 2.88E–04 -0.239 7.69E–05 0.321 1.72E-05
rs4392391 C3orf23 0.419 3 44247970 Downstream 1555906_s_at C3orf23 3 -0.318 5.78E–05 -0.250 3.46E–05 0.263 4.86E–04
rs1565214 C3orf23 0.425 3 44309303 Upstream 1555906_s_at C3orf23 3 -0.308 1.35E–04 -0.251 4.09E–05 0.263 4.86E–04
rs9809107 C3orf23 0.419 3 44257938 Flanking_5UTR 1555906_s_at C3orf23 3 -0.301 1.46E–04 -0.242 5.97E–05 0.263 4.86E–04
rs967285 C3orf23 0.422 3 44250280 Downstream 1555906_s_at C3orf23 3 -0.301 1.48E–04 -0.247 4.36E–05 0.263 4.86E–04
rs9821268 C3orf23 0.413 3 44278128 Upstream 1555906_s_at C3orf23 3 -0.292 2.43E–04 -0.241 6.29E–05 0.263 4.86E–04
rs1565215 C3orf23 0.418 3 44309103 Upstream 1555906_s_at C3orf23 3 -0.291 2.64E–04 -0.246 4.62E–05 0.263 4.86E–04
rs10510741 C3orf23 0.445 3 44239198 Flanking_5UTR 1555906_s_at C3orf23 3 -0.283 3.68E–04 -0.275 4.71E–06 0.263 4.86E–04
rs9852733 C3orf23 0.451 3 44252343 Flanking_5UTR 1555906_s_at C3orf23 3 -0.279 4.59E–04 -0.268 8.53E–06 0.263 4.86E–04
rs6808448 C3orf23 0.451 3 44218611 Flanking_5UTR 1555906_s_at C3orf23 3 -0.273 6.19E–04 -0.273 5.38E–06 0.263 4.86E–04
rs9846155 C3orf23 0.456 3 44257844 Flanking_5UTR 1555906_s_at C3orf23 3 -0.272 6.33E–04 -0.262 1.38E–05 0.263 4.86E–04
rs9284879 C3orf23 0.433 3 44259588 Flanking_5UTR 1555906_s_at C3orf23 3 -0.264 9.43E–04 -0.253 2.65E–05 0.263 4.86E–04
rs12486452 C3orf23 0.433 3 44299569 Flanking_5UTR 1555906_s_at C3orf23 3 -0.264 9.43E–04 -0.241 6.45E–05 0.263 4.86E–04
rs12631341 C3orf23 0.433 3 44284272 Flanking_5UTR 1555906_s_at C3orf23 3 -0.264 9.43E–04 -0.241 6.45E–05 0.263 4.86E–04
rs7631790 C3orf23 0.433 3 44274209 Flanking_5UTR 1555906_s_at C3orf23 3 -0.264 9.43E–04 -0.241 6.45E–05 0.263 4.86E–04
rs4392391 C3orf23 0.419 3 44247970 Downstream 227978_s_at ZADH2 18 -0.318 5.78E–05 0.251 3.11E–05 -0.351 2.42E–06
rs1565214 C3orf23 0.425 3 44309303 Upstream 227978_s_at ZADH2 18 –0.308 1.35E–04 0.246 5.9E–05 -0.351 2.42E–06
rs9809107 C3orf23 0.419 3 44257938 Flanking_5UTR 227978_s_at ZADH2 18 -0.301 1.46E–04 0.273 5.72E–06 -0.351 2.42E–06
rs967285 C3orf23 0.422 3 44250280 Downstream 227978_s_at ZADH2 18 -0.301 1.48E–04 0.254 2.58E–05 -0.351 2.42E–06
rs9821268 C3orf23 0.413 3 44278128 Upstream 227978_s_at ZADH2 18 -0.292 2.43E–04 0.247 4.17E–05 -0.351 2.42E–06
rs1565215 C3orf23 0.418 3 44309103 Upstream 227978_s_at ZADH2 18 -0.291 2.64E–04 0.250 3.46E–05 -0.351 2.42E–06
rs4682949 C3orf23 0.398 3 44220159 Flanking_5UTR 227978_s_at ZADH2 18 -0.287 3.01E–04 0.247 4.14E–05 –0.351 2.42E–06
rs10510741 C3orf23 0.445 3 44239198 Flanking_5UTR 227978_s_at ZADH2 18 -0.283 3.68E–04 0.251 3.03E–05 –0.351 2.42E–06


















Table 2 Integrated analyses for drug response for either (A) Gemcitabine or (B) AraC (Continued)
rs6808448 C3orf23 0.451 3 44218611 Flanking_5UTR 227978_s_at ZADH2 18 -0.273 6.19E–04 0.260 1.62E–05 -0.351 2.42E–06
rs9846155 C3orf23 0.456 3 44257844 Flanking_5UTR 227978_s_at ZADH2 18 -0.272 6.33E–04 0.260 1.58E–05 -0.351 2.42E–06
rs12486452 C3orf23 0.433 3 44299569 Flanking_5UTR 227978_s_at ZADH2 18 -0.264 9.43E–04 0.239 7.52E–05 -0.351 2.42E–06
rs12631341 C3orf23 0.433 3 44284272 Flanking_5UTR 227978_s_at ZADH2 18 -0.264 9.43E–04 0.239 7.52E–05 -0.351 2.42E–06
rs7631790 C3orf23 0.433 3 44274209 Flanking_5UTR 227978_s_at ZADH2 18 -0.264 9.43E–04 0.239 7.52E–05 -0.351 2.42E–06
rs12188464 PIK3RI 0.459 5 67999705 Flanking_5UTR 225935_at ––– 7 -0.309 9.69E–05 0.366 2.47E–06 -0.296 7.99E–05
rs13171512 PIK3RI 0.462 5 68000787 Flanking_5UTR 236170_x_at ––– 7 -0.313 7.86E–05 0.349 7.69E–06 -0.299 6.75E–05
rs13171512 PIK3RI 0.462 5 68000787 Flanking_5UTR 225935_at ––– 7 -0.313 7.86E–05 0.375 1.33E–06 -0.296 7.99E–05
rs7713001 PIK3RI 0.459 5 67999371 Flanking_5UTR 225935_at ––– 7 -0.309 9.69E–05 0.366 2.47E–06 -0.296 7.99E–05
rs12188464 PIK3RI 0459 5 67999705 Flanking_5UTR 201334_s_at ARHGEF12 11 -0.309 9.69E–05 0.380 9.03E–07 -0.339 5.35E–06
rs13171512 PIK3RI 0.462 5 68000787 Flanking_5UTR 201334_s_at ARHGEF12 11 -0.313 7.86E–05 0.372 1.59E–06 -0.339 5.35E–06
rs7713001 PIK3RI 0.459 5 67999371 Flanking_5UTR 201334_s_at ARHGEF12 11 -0.309 9.69E–05 0.380 9.03E–07 -0.339 5.35E–06
rs12188464 PIK3RI 0.459 5 67999705 Flanking_3UTR 238012_at DPP7 9 -0.309 9.69E–05 0.372 1.63E–06 -0.324 1.45E–05
rs13171512 PIK3RI 0.462 5 68000787 Flanking_3UTR 238012_at DPP7 9 -0.313 7.86E–05 0.378 1.08E–06 -0.324 1.45E–05
rs7713001 PIK3RI 0.459 5 67999371 Flanking_3UTR 238012_at DPP7 9 -0.309 9.69E–05 0.372 1.63E–06 -0.324 1.45E–05
rs12188464 PIK3RI 0.459 5 67999705 Flanking_3UTR 225086_at FAM98B 15 -0.309 9.69E–05 0.345 9.5E–06 -0.352 2.18E–06
rs13171512 PIK3RI 0.462 5 68000787 Flanking_3UTR 225086_at FAM98B 15 -0.313 7.86E–05 0.354 5.38E–06 -0.352 2.18E–06
rs3135351 HLA–DRA 0.137 6 32500923 Flanking_5UTR 1566082_at ––– 10 0.265 9.48E–04 0.277 4.24E–06 0.320 1.88E–05
rs2472476 NIPSNAP3B 0.389 9 106571777 Intron 200988_s_at PSME3 17 0.338 1.92E–05 -0.239 7.6E–05 -0.350 .60E–06
rs2928445 IPMK 0.267 10 58816782 Flanking_3UTR 227482_at ADCK1 14 -0.331 2.76E–05 0.247 4.09E–05 -0.293 9.45E–05
rs12244977 IPMK 0.195 10 58762688 Flanking_3UTR 1569396_at RAB40C 16 -0.308 1.03E–04 -0.243 5.72E–05 0.303 5.47E–05
rs12256364 IPMK 0.195 10 58765694 Flanking_3UTR 1569396_at RAB40C 16 -0.308 1.03E–04 -0.243 5.72E–05 0.303 5.47E–05
rs2928445 IPMK 0.267 10 58816782 Flanking_3UTR 226987_at RBM15B 3 -0.331 2.76E–05 0.263 1.2E–05 -0.354 1.90E–06
rs4774760 PIGB 0.416 15 53376504 upstreaintronm 224856_at FKBP5 6 0.326 3.63E–05 -0.241 6.7E–05 -0.411 2.15E–08
rs7174876 PIGB 0.416 15 53406853 Upstream 224856_at FKBP5 6 0.284 4.06E–04 -0.237 9.71E–05 -0.411 2.15E–08
rs2290344 PIGB 0.253 15 53407088 Coding 224856_at FKBP5 6 0.339 1.75E–05 -0.266 9.87E–06 -0.393 9.66E–08
rs4774760 PIGB 0.416 15 53376504 Upstream 204560_at FKBP5 6 0.326 3.63E–05 -0.282 2.7E–06 -0.393 9.66E–08
rs12050587 PIGB 0.45 15 53414820 Intron 224856_at FKBP5 6 0.305 1.23E–04 -0.256 2.27E–05 -0.393 9.66E–08
rs28668016 PIGB 0.365 15 53398725 5UTR 204560_at FKBP5 6 0.304 1.31E–04 -0.261 1.49E–05 -0.393 9.66E–08
rs11636687 PIGB 0.421 15 53392444 Flanking_5UTR 224856_at FKBP5 6 0.302 1.53E–04 -0.252 3.34E–05 -0.393 9.66E–08
rs2414409 PIGB 0.448 15 53419009 Intron 204560_at FKBP5 6 0.299 1.62E–04 -0.264 1.17E–05 -0.393 9.66E–08
rs7183960 PIGB 0.451 15 53409987 Intron 224856_at FKBP5 6 0.292 2.37E–04 -0.262 1.37E–05 -0.393 9.66E–08


















Table 2 Integrated analyses for drug response for either (A) Gemcitabine or (B) AraC (Continued)
rs2290344 PIGB 0.253 15 53407088 Coding 224856_at PIGB 15 0.339 1.75E–05 -0.301 4.81E–07 -0.294 8.98E–05
rs4774760 PIGB 0.416 15 53376504 Upstream 242760_x_at PIGB 15 0.326 3.63E–05 -0.240 6.85E–05 -0.294 8.98E–05
rs8024695 PIGB 0.285 15 53426597 Intron 242760_x_at PIGB 15 0.321 5.00E–05 -0.282 2.56E–06 -0.294 8.98E–05
rs28668016 PIGB 0.365 15 53398725 5UTR 242760_x_at PIGB 15 0.304 1.31E–04 -0.274 5.28E–06 -0.294 8.98E–05
(B) AraC
rs10495285 KIAA0133 (URB2) 0.171 1 227871618 Downstream 219526_at C14orf169 14 0.393 4.13E–07 -0.240 6.97E–05 -0.318 1.86E–05
rs9861198 Probable leucyl–
tRNA synthetase
0.086 3 45310394 Upstream 235936_at LOC254559 15 0.308 9.07E–05 0.274 5.12E–06 0.294 8.27E–05
rs9816196 U3 small
nucleolar RNA
0.055 3 45321382 Upstream 235936_at LOC254559 15 0.315 6.70E–05 0.242 7.05E–05 0.294 8.27E–05
rs6441911 RIS1 0.055 3 45322523 Flanking_5UTR 235936_at LOC254559 15 0.315 6.20E–05 0.250 3.26E–05 0.294 8.27E–05
rs9878275 Probable leucyl–
tRNA synthetase
0.055 3 45331043 Upstream 235936_at LOC254559 15 0.311 8.31E–05 0.249 3.79E–05 0.294 8.27E–05
rs9846284 U3 small
nucleolar RNA
0.055 3 45331970 Upstream 235936_at LOC254559 15 0.315 6.20E–05 0.250 3.37E–05 0.294 8.27E–05
rs9850725 LARS2 0.055 3 45332431 Flanking_5UTR 235936_at LOC254559 15 0.315 6.20E–05 0.250 3.26E–05 0.294 8.27E–05
rs9861198 Probable leucyl–
tRNA synthetase
0.086 3 45310394 Upstream 206603_at SLC2A4 17 0.308 9.07E–05 0.239 7.63E–05 0.345 3.18E–06
rs9816196 U3 small
nucleolar RNA
0.055 3 45321382 Upstream 206603_at SLC2A4 17 0.315 6.70E–05 0.294 1.21E–06 0.345 3.18E–06
rs6441911 RIS1 0.055 3 45322523 Flanking_5UTR 206603_at SLC2A4 17 0.315 6.20E–05 0.301 4.80E–07 0.345 3.18E–06
rs9878275 Probable leucyl–
tRNA synthetase
0.055 3 45331043 Upstream 206603_at SLC2A4 17 0.311 8.31E–05 0.300 5.67E–07 0.345 3.18E–06
rs9846284 U3 small
nucleolar RNA
0.055 3 45331970 Upstream 206603_at SLC2A4 17 0.315 6.20E–05 0.301 5.03E–07 0.345 3.18E–06
rs9850725 LARS2 0.055 3 45332431 Flanking_5UTR 206603_at SLC2A4 17 0.315 6.20E–05 0.301 4.80E–07 0.345 3.18E–06
rs9816196 U3 small
nucleolar RNA
0.055 3 45321382 Upstream 1553755_at NXNL1 19 0.315 6.70E–05 0.237 9.98E–05 0.312 2.82E–05
rs6441911 RIS1 0.055 3 45322523 Flanking_5UTR 1553755_at NXNL1 19 0.315 6.20E–05 0.245 4.73E–05 0.312 2.82E–05
rs9878275 Probable leucyl–
tRNA synthetase
0.055 3 45331043 Upstream 1553755_at NXNL1 19 0.311 8.31E–05 0.244 5.26E–05 0.312 2.82E–05
rs9846284 U3 small
nucleolar RNA
0.055 3 45331970 Upstream 1553755_at NXNL1 19 0.315 6.20E–05 0.245 4.88E–05 0.312 2.82E–05
rs9850725 LARS2 0.055 3 45332431 Flanking_5UTR 1553755_at NXNL1 19 0.315 6.20E–05 0.245 4.73E–05 0.312 2.82E–05
rs17564430 IGSF4 (CADM1) 0.155 11 114548784 Flanking_3UTR 206571_s_at MAP4K4 2 -0.337 1.74E–05 0.237 8.48E–05 -0.322 1.51E–05
rs11215406 IGSF4 (CADM1) 0.138 11 Intron114570292 Intron 206571_s_at MAP4K4 2 -0.335 1.92E–05 0.248 3.93E–05 -0.322 1.51E–05


















Table 2 Integrated analyses for drug response for either (A) Gemcitabine or (B) AraC (Continued)
rs17564430 IGSF4 (CADM1) 0.155 11 114548784 Flanking_3UTR 204880_at MGMT 10 -0.337 1.74E–05 -0.236 9.07E–05 0.332 7.44E–06
rs17564430 IGSF4 (CADM1) 0.155 11 114548784 Flanking_3UTR 1556095_at UNC13C 15 -0.337 1.74E–05 0.256 2.21E–05 -0.354 1.60E–06
rs17564430 IGSF4 (CADM1) 0.155 11 114548784 Flanking_3UTR 1556096_s_at UNC13C 15 -0.337 1.74E–05 0.240 7.07E–05 -0.337 5.47E–06
rs17564430 IGSF4 (CADM1) 0.155 11 114548784 Flanking_3UTR 1569969_a_at UNC13C 15 -0.337 1.74E–05 0.257 1.93E–05 -0.332 7.56E–06
rs11215406 IGSF4 (CADM1) 0.138 11 114570292 Intron 1556095_at UNC13C 15 -0.335 1.92E–05 0.276 4.27E–06 -0.354 1.60E–06
rs11215406 IGSF4 (CADM1) 0.138 11 114570292 Intron 1556096_s_at UNC13C 15 -0.335 1.92E–05 0.255 2.29E–05 -0.337 5.47E–06
rs11215406 IGSF4 (CADM1) 0.138 11 114570292 Intron 1569969_a_at UNC13C 15 -0.335 1.92E–05 0.270 7.08E–06 -0.332 7.56E–06
rs11215416 IGSF4 (CADM1) 0.147 11 114582537 Intron 1556095_at UNC13C 15 -0.346 9.57E–06 0.260 1.59E–05 -0.354 1.60E–06
rs11215416 IGSF4 (CADM1) 0.147 11 114582537 Intron 1556096_s_at UNC13C 15 -0.346 9.57E–06 0.242 6.21E–05 -0.337 5.47E–06
rs11215416 IGSF4 (CADM1) 0.147 11 114582537 Intron 1569969_a_at UNC13C 15 -0.346 9.57E–06 0.258 1.84E–05 -0.332 7.56E–06
rs2008801 IGSF4 (CADM1) 0.126 11 114513385 Flanking_3UTR 225532_at CABLES1 18 -0.317 5.42E–05 -0.254 2.54E–05 0.271 2.92E–04
rs2507905 IGSF4 (CADM1) 0.126 11 114513815 Downstream 225532_at CABLES1 18 -0.317 5.42E–05 -0.254 2.54E–05 0.271 2.92E–04
rs7122402 IGSF4 (CADM1) 0.126 11 114521517 Downstream 225532_at CABLES1 18 -0.317 5.42E–05 -0.261 1.43E–05 0.271 2.92E–04
rs4938179 IGSF4 (CADM1) 0.132 11 114538635 Downstream 225532_at CABLES1 18 -0.289 2.56E–04 -0.247 4.34E–05 0.271 2.92E–04
rs17564430 IGSF4 (CADM1) 0.155 11 114548784 Flanking_3UTR 225532_at CABLES1 18 -0.337 1.74E–05 -0.242 6.19E–05 0.271 2.92E–04
“Integrated analyses” with the top expression probe sets that were associated with SNPs within loci with gemcitabine IC50 (SNP vs. Expression P value <10–4, and Expression vs. IC50 P value < 10–4), except for C3orf23
(SNP vs. Expression P value < 10–4, and Expression vs. IC50 P value ≈ 10–4). Eighteen unique probe sets, representing 12 annotated genes that were associated with 66 SNPs within 7 loci and were significantly
correlated with gemcitabine IC50 values are listed. (B) “Integrated analyses” for AraC. Eleven unique probe sets, representing 6 annotated genes that were associated with 15 SNPs within 3 loci and were significantly


















Table 3 Functional studies of candidate genes
Gene symbol Selection strategy Cytotoxicity validation in cancer cell lines
SNP vs. IC50 Integrated analysis Both SU86 and MDA231 Either THP-1 or BDCM
SNP Location P < 10-4 SNP vs. Exp P < 10-4 (cancer cell lines) (leukemia cell lines)
Exp vs. IC50 P <10-4
PIGB Intron/coding/5UTR/3UTR Gem Gem Yes NP
C3orf23 5UTR/upstream Gem Gem No NP
ZADH2 Gem Yes NP
ARHGEF12 Gem No NP
DPP7 Gem No NP
PSME3 Gem Yes NP
NIPSNAP3B Intron/5UTR Gem No NP
PIK3R1 Flanking_5UTR/3UTR Gem No NP
DOK6 Intron Gem Yes NP
TGFBI Flanking_5UTR Gem Yes NP
UNC13C AraC No No
C14orf169 AraC Yes NP
MAP4K4 AraC No NP
URB2 Downstream AraC No No
TUSC3 Intron/5UTR/3UTR AraC Yes No
LARS2 5UTR AraC Yes No
RIS1 (TMEM158) 5UTR AraC Yes Yes
IGSF4 (CADM1) Intron/downstream/3UTR AraC No No
LNX2 Intron/5UTR/3UTR AraC Yes No
SMC2 3UTR AraC Yes Yes
PLD5 Intron Both No NP
GPR98 Intron Both No No
HLA-DRA Intron/3UTR Both Yes No
ZNF215 Flanking_5UTR/3UTR/coding Both No No
CABLES1 Both No No
The table lists the top 26 candidate genes selected for siRNA screening for both gemcitabine and AraC, with MTS assay results as well as QRT-PCR assay results
when appropriate.
A total of 26 genes were selected for siRNA screening, with 11 genes for gemcitabine, 10 for AraC, and 5 for both. For the validation assays with MTS and
QRT-PCR, “Yes” indicates that knockdown of the gene altered drug cytotoxicity, while “No” indicates no alteration. “NP” indicates not performed. The genes that
are bolded were functionally validated.
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http://www.biomedcentral.com/1471-2164/15/93labeled with biotin and electrophoresis was performed
with 5% acrylamide gels, followed by autoradiography.
Competition experiments were performed with excess
non-labeled probe.Genome-wide gene expression and SNP analysis
Expression array data were obtained for all 174 lympho-
blastoid cell lines (LCLs) as previously described [17].
Illumina HumanHap550K and 510S BeadChips, which
assayed 561,298 and 493,750 SNPs, respectively, were
used to obtain genome-wide SNP data for these LCLs
[23]. Genotyping was performed in the Genotype Shared
Resource (GSR) at the Mayo Clinic, Rochester, MN. We
also obtained publicly available Affymetrix SNP Array6.0 Chip SNP data which involved 643,600 SNPs unique
to the Affymetrix SNP array for the same cell lines. After
quality control (QC), SNPs with call rates <0.95, Hardy-
Weinberg Equilibrium (HWE) P values < 0.001, or MAFs
<5% were excluded, as were DNA samples with call rates
<0.95. A total of 1,348,798 SNPs that passed QC were
used to perform the association studies.Imputation analysis
SNPs not genotyped were imputed across a region
200 kb up or downstream of the selected genes harbor-
ing or close to the SNPs associated with drug response
in the LCLs. Imputation was performed using Beagle
(v3.3.1) [24] with the 11/23/2010 release of the 1000
Figure 2 Schematic diagram of the strategy for candidate gene selection for functional validation. Genome-wide association studies for
either gemcitabine or AraC cytotoxicity were performed with 1.3 million SNPs or 54,000 expression probe sets. “Integrated analyses” were
performed using SNP “loci” that contained at least 2 SNPs (P < 10-4) or 1 SNP (P < 10-4) plus 3 SNPs (P < 10-3) within 100 kb surrounding the top
significant SNPs, 54,000 expression probe sets and IC50 values to identify SNPs associated with drug IC50 values through their influence on gene
expression (SNP-Expression P value <10-4, Expression-IC50 P value <10-4). Finally, 26 candidate genes, including 11 for gemcitabine, 10 for AraC,
and 5 for both, were selected for functional validation studies that were performed with multiple cancer cell lines.
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http://www.biomedcentral.com/1471-2164/15/93Genomes project as a reference population [25]. Im-
puted SNPs with a dosage R2 quality measure of less
than 0.3, and SNPs with MAF <0.01 were not included
in the analysis. Four of the imputed SNPs were geno-
typed for validation, the average squared difference
between the count of the same allele in the imputed and
genotyped version of these SNPs was computed to
measure the concordance of the imputed genotype with
actual genotype, a smaller difference indicating greater
concordance.Statistical methods
Partial Pearson correlations were used to quantify the
association between: SNPs and mRNA expression; SNPs
and IC50; and mRNA expression and IC50. IC50 was
transformed to remove skewness using a log transform-
ation for gemcitabine and van der Waerden rank trans-
formation for AraC. The adjustment variables in the
partial correlation were race and gender if SNPs were
not involved; or race, gender and five eigenvectors con-
trolling for population stratification as described previ-
ously [23]. These partial correlations were tested using a
Wald test, false discovery q-values [26] were also com-
puted for each test.Results
Genome-wide SNP vs. drug cytotoxicity association study
and imputation analysis
Previously, we had performed GWAS using only the
550 k SNP data set for this cell line system [18]. In the
current study, we expand the SNPs studies to include
additional Illumina SNPs as well as publically available
SNP data obtained with Affymetrix 6.0 SNP data for the
same cell lines to identify additional novel potential
pharmacogenomic biomarkers. As a result, we performed
an analysis for the association of 1,348,798 SNPs with
IC50 values for gemcitabine and AraC (Figure 1A and
1B). The most significant SNP for gemcitabine was
rs1598848 with a P value 7.08 × 10-7 (r = −0.391, MAF =
0.473), while the most significant SNP for AraC was
rs4078252 with a P value 1.54 × 10-7 (r = 0.405, MAF =
0.198) (Additional file 1: Table S1A and B). Fourteen SNPs
for gemcitabine and 34 for AraC had P values <10-5, and
143 SNPs for gemcitabine and 204 SNPs for AraC had P
values <10-4, respectively. One hundred and twenty six
SNPs with P < 10-3 were common to both drugs
(Additional file 1: Table S1C). To explore ungenotyped
SNPs that might be functional, we imputed SNPs sur-
rounding the selected genes (+/−200 kb) harboring or


































































































































































































Figure 3 (See legend on next page.)
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(See figure on previous page.)
Figure 3 Functional characterization of candidate genes. Knockdown of individual genes in cancer cell lines followed by MTS assays to
determine the effect of the candidate gene on gemcitabine. Data are shown for 11 validated out of the 26 candidate genes tested in SU86,
MDA-MB-231, BDCM, and THP-1 cancer cell lines by MTS assay after siRNA knockdown performed with a pool of 4 specific siRNAs. The drug dose
response curves were obtained with the MTS assays. Red lines indicate the negative control siRNA pool, while blue lines indicate data obtained
with specific siRNA pool. The x-axis indicates the log10 gemcitabine concentration and the y-axis indicates the proportion of cells surviving after
drug exposure. The bar graphs at the bottom show knockdown efficiency tested by QRT-PCR assay using the same transfected cells as those used
to perform the MTS assays. The y-axis indicates relative gene expression after siRNA knockdown when compared with negative control siRNA.
The experiments were repeated 3 times and the error bar represents SEM. Each of the genes was significantly knocked down when compared to
the negsiRNA control, P<0.05.
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http://www.biomedcentral.com/1471-2164/15/93Genomes data as a reference (Additional file 1: Figure
S1A, B, and C). Besides the “observed SNPs” on the geno-
typing platforms, there were 23 imputed SNPs for gemci-
tabine and 35 for AraC, respectively, that were also
associated with drug response IC50 values (P < 10-4)
(Additional file 1: Table S2A and B). In order to determine
the accuracy of imputation, we selected 6 imputed SNPs
(rs10447475, rs4621668, rs11215400, rs10926784, rs3196512
and rs7762319) that were among the top two SNPs from
each gene region associated with drug response IC50s
(P < 10-3) to genotype using Taqman assay. Four SNPs
((rs10447475, rs4621668, rs11215400 and rs10926784)
were successfully genotyped. The average squared dif-
ference between the count of the same allele in the im-
puted and genotyped version of these 4 SNPs was low
ranging from 0.02-0.065 indicating that the concord-
ance was high (Additional file 1: Figure S2).
“Integrated analyses” of SNP loci, basal expression and
drug cytotoxicity
We also performed integrated analyses of SNPs, expres-
sion array and cytotoxicity data [18,23]. To do that, we
began with SNPs that had P values <10-3. We selected a
less stringent P value cutoff to include as many potential
candidates as possible for follow-up functional genomic
studies. Next, we tested expression probe sets that were
associated with these SNPs, followed by association of
those expression probe sets with drug IC50 values, ie we
performed an “integrated analysis”. In these analyses, we
used SNP loci, defined as a region that contained at least
2 SNPs with P < 10-4 or 1 SNP with P < 10-4, plus 3 add-
itional SNPs with P < 10-3 within +/−100 kb surrounding
the most significant SNPs. All of the SNPs within each
of those loci are listed in Additional file 1: Table S2,
which includes genotyped as well as imputed SNPs. We
identified 11 loci containing 166 SNPs for gemcitabine
and 23 loci with 187 SNPs for AraC that were associated
with IC50 values for these two drugs, respectively (Table 1).
Four loci containing 4 genes – HLA-DRA, ZNF215, MASS1,
and PLD5 – were common to both drugs (Table 1).
The integrated analyses identified 66 SNPs in 6 loci
that were associated with gemcitabine IC50 values and
the expression of 12 genes represented by 17 probesets.
Those 17 probesets were also associated with gemcitabineIC50 values (P < 10-4). The integrated analyses also identi-
fied 36 SNPs in 3 loci that were associated with AraC
IC50 values and the expression of 9 genes (10 probesets)
(Table 2). For gemcitabine, 19 SNPs were within cis-regulatory
regions for PIGB or C3orf23. No cis- regulation be-
tween SNP and gene expression was identified for
AraC. Of interest, SNPs in PIGB were associated with
the expression of that gene (lowest P = 5.97 × 10-9) as
well as the expression of FKBP5 (lowest P = 2.70 × 10-6), a
gene that we previously reported to play an important role
in response to gemcitabine and AraC as well as many
other chemotherapeutic agents including gemcitabine and
AraC [17,27]. We next moved to further analyses of candi-
date genes identified during the integrated analysis.
Follow-up functional validation of candidate genes in
cancer cells
Since the regulation of gene expression is tissue specific
[28], we wanted to functionally validate in cancer cell
lines candidate genes selected based on our analysis per-
formed with LCLs. The tumor cell lines that we selected
were based on the expression of the genes of interest
and on the clinical uses of these two drugs. Gemcitabine
is used in the treatment of pancreatic cancer but it is
also used to treat other solid tumors such as breast can-
cer, while AraC is first-line therapy for acute myeloge-
nous leukemia (AML). Therefore, we selected one
human pancreatic cancer cell line, SU86, one breast can-
cer cell line, MDA-MB-231 and two leukemia cell lines,
BDCM and THP1, to functionally characterize the genes
of interest. Twenty-six genes were selected based on a
series of criteria including association P value, SNP
locus, whether the gene was expressed in LCLs and the
biological function of the genes (Table 3 and Figure 2).
To determine the functional impact of those genes, we
used specific siRNA pools to knockdown the 26 candi-
date genes, followed by QRT-PCR and MTS cytotoxicity
assay. Eleven genes showed an effect on gemcitabine
cytotoxicity, 10 on AraC and 5 were common to both
drugs. Knockdown of PIGB, ZADH2, PSME3, DOK6,
TGFBI, and HLA-DRA in both SU86 and MDA-MB-231
cells significantly desensitized the cells to gemcitabine
(Table 3 and Figure 3), consistent with the association
study results. Knockdown of C4orf169, TUSC3, LNX2,
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Figure 4 Functional characterization of candidate genes. Knockdown of individual genes in cancer cell lines followed by MTS assays to
determine the effect of the candidate gene on AraC. Data are shown for 11 validated out of the 26 candidate genes tested in SU86,
MDA-MB-231, BDCM, and THP-1 cancer cell lines by MTS assay after siRNA knockdown performed with a pool of 4 specific siRNAs. The drug dose
response curves were obtained with the MTS assays. Red lines indicate the negative control siRNA pool, while blue lines indicate data obtained
with specific siRNA pool. The x-axis indicates the log10 AraC concentration and the y-axis indicates the proportion of cells surviving after drug
exposure. The bar graphs at the bottom show knockdown efficiency tested by QRT-PCR assay using the same transfected cells as those used to
perform the MTS assays. The y-axis indicates relative gene expression after siRNA knockdown when compared with negative control siRNA.
The experiments were repeated 3 times and the error bar represents SEM. Each of the genes was significantly knocked down when compared to
the negsiRNA control, P<0.05.
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Figure 5 Effect of candidate genes on apoptosis in SU86 cells. Apoptosis was measured in SU86 cancer cell line after transfection with a
pool of 4 specific siRNAs for 24 h and exposure to gemcitabine (A) or AraC (B) for an additional 48 h, followed by Caspase-3/7 assay. The x-axis
indicates the drug dose and the y-axis represents the relative Caspase 3/7 activity normalized to nontreatment control. P values represented the
significant difference in the AUC values derived from the curves between the control and specific knockdown.
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http://www.biomedcentral.com/1471-2164/15/93RIS1, and SMC2 and HLA-DRA in both SU86 and
MDA-MB-231 cells significantly desensitized the cells to
AraC (Table 3 and Figure 4). Finally, knockdown of
HLA-DRA in THP-1 leukemia cells, LNX2 in BDCMcells, and SMC2 and RIS1 in both THP1 and BDCM
cells also desensitized the cells to AraC, results
that were also consistent with our association results
(Figure 4).


























PIGB Decrease No No No No No Decrease Decrease No Decrease Decrease
ZADH2 Decrease No No No No No No Increase No No No
PSME3 Decrease No Increase No Decrease No No Increase Decrease No No
DOK6 Decrease No No No No No Decrease No No No Decrease
TGFBI Decrease No No Increase No No Decrease Decrease Decrease Decrease Decrease
C14orf169 Decrease No Increase Increase No No Increase Increase No Increase Increase
TUSC3 Decrease No No No Decrease Decrease No No Decrease No No
RIS1
(TMEM158)
No No No No No No No Increase No No No
LNX2 No No No No No No No No No Increase No
SMC2 No No No No No No No No No No No
HLA-DRA Decrease No Increase No No No Increase No No No No
Functional characterization of 11 genes using the Cancer-related Cignal Reporter Array (SABioscience).
Transcription factors for each signal pathway are listed in parenthesis. “Increase” means at least a 2-fold increase of luciferase activity in cells treated with specific siRNA compared with cells treated with negative


















Figure 6 Effect of candidate gene knockdown on 10 cancer related pathways in SU86 cells. The Cancer Cignal Reporter assay was used to
determine the effect of candidate gene knockdown on 10 cancer related signaling pathways. Each column indicates relative luciferase activity of
the transcription factor-transfected SU86 cells. The x-axis indicates individual TF dependent cancer signaling pathways. * indicates P < 0.05 as
compared to control cells, while ** indicates P < 0.01.
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Table 5 The top seven SNPs in PIGB that were associated with gemcitabine cytotoxicity and its expression in LCLs by
integrated analysis
SNP Gene SNP vs. IC50 SNP vs. Expression Expression vs. IC50
rsID Chr Position Region MAF Probeset Gene symbol Chr R value P value R value P value R value P value
rs2290344 15 53407088 Coding 0.253 205452_at PIGB 15 0.339 1.75E-05 −0.340 1.06E-08 −0.212 5.31E-03
rs2290344 15 53407088 Coding 0.253 242760_x_at PIGB 15 0.339 1.75E-05 −0.301 4.81E-07 −0.294 8.98E-05
rs4774760 15 53376504 5′-upstream 0.416 205452_at PIGB 15 0.326 3.63E-05 −0.283 2.48E-06 −0.212 5.31E-03
rs4774760 15 53376504 5′-upstream 0.416 242760_x_at PIGB 15 0.326 3.63E-05 −0.240 6.85E-05 −0.294 8.98E-05
rs8024695 15 53426597 Intron 0.285 205452_at PIGB 15 0.321 5.00E-05 −0.326 4.60E-08 −0.212 5.31E-03
rs8024695 15 53426597 Intron 0.285 242760_x_at PIGB 15 0.321 5.00E-05 −0.282 2.56E-06 −0.294 8.98E-05
rs12050587 15 53414820 Intron 0.450 205452_at PIGB 15 0.305 1.23E-04 −0.246 4.54E-05 −0.212 5.31E-03
rs28668016 15 53398725 5′-UTR 0.365 205452_at PIGB 15 0.304 1.31E-04 −0.346 5.97E-09 −0.212 5.31E-03
rs28668016 15 53398725 5′-UTR 0.365 242760_x_at PIGB 15 0.304 1.31E-04 −0.274 5.28E-06 −0.294 8.98E-05
rs11636687 15 53392444 5′-upstream 0.421 205452_at PIGB 15 0.302 1.53E-04 −0.287 2.22E-06 −0.212 5.31E-03
rs7174876 15 53406853 Intron 0.423 205452_at PIGB 15 0.284 4.06E-04 −0.261 1.64E-05 −0.212 5.31E-03
R values represent correlation coefficients for associations. We performed integrated analysis among the SNPs and mRNA expression of the PIGB gene as well as
gemcitabine cytotoxicity. The only cis-associated SNPs with PIGB gene expression were listed.
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http://www.biomedcentral.com/1471-2164/15/93We next wanted to determine whether the cytotoxic
effects of those genes might involve apoptosis. There-
fore, we performed caspase-3/7 activity assays after
knockdown of the candidate genes in SU86 cells. As
shown in Figure 5A and 5B, down-regulation of PIGB,
DOK6, TGFBI, ZADH2, PSME3, and HLA-DRA in
SU86 cells significantly decreased caspase-3/7 activity
after treatment with gemcitabine as compared with
negative control siRNA-treated cells. Similar results were
also observed for AraC treatment following siRNA
knockdown of TUSC3, C14orf169, and HLA-DRA.
However, knockdown of LNX2, RIS1, and SMC2 did not
alter the cellular caspase-3/7 activity (Table 4), suggest-
ing that a different mechanism was involved.
Finally, we used the Cancer Cignal Finder Array
(SABioscience) that consists of 10 dual-luciferase re-
porter gene assays to determine whether our candidate
genes might affect any of the 10 cancer-related signaling
pathways in SU86 cells by measuring changes in tran-
scriptional activities of 10 key transcription factors (TF)
after knockdown of each candidate gene. We observed
changes in transcriptional activity of several TFs after
knockdown of specific genes in SU86 cells, suggesting
that these genes might be involved in the regulation of a
particular cancer-related signaling pathway or pathways
that might contribute to resistance to gemcitabine and
AraC (Figure 6 and Table 3). For example, knockdown
of PIGB resulted in a decrease in transcriptional activity
of Elk-1/SRF, AP1, NFκB, and Myc/MAX in SU86 cells,
indicating a down-regulation of these signaling path-
ways. Knockdown of DOK6 dramatically decreased the
transcription activities of both NFκB and AP1 in the
NFκB and MAPK/JNK pathways, while the activity of
the transcription factor Myc/MAX that is involved inthe c-Myc pathway was increased significantly after
ZADH2 knockdown. However, we did not observe any
significant changes after SMC2 knockdown.
Functional characterization of PIGB SNPs
When we performed integrated analysis among SNPs,
gene expression and gemcitabine cytotoxicity, we found
that the only cis-regulated SNPs mapped to PIGB.
Knockdown of PIGB resulted in desensitization of can-
cer cells to gemcitabine. PIGB contained 7 SNPs that
were associated both with gemcitabine response (P < 10-3)
and with its own gene expression (P < 10-4) (Table 5).
PIGB expression was also significantly correlated with
gemcitabine cytotoxicity (P = 8.95 × 10-5 and P= 5.31 × 10-3
for two different probe sets for PIGB mRNA). We also
determined LD patterns for those 7 SNPs using HapMap
data for each ethnic group. As shown in Figure 7A, LD
patterns differed among the three ethnic groups. In both
CHB/JPT and CEPH groups, those 7 SNPs were in tight
LD, while there was not significant linkage among the
SNPs in the YRI population. The top 3 SNPs in PIGB, in-
cluding rs2290344, a nonsynonymous coding SNP (M161T)
in exon 4, rs28668016 in the 5′-UTR, and rs11636687
in the 5′ flanking region (Table 5) were selected for
further functional characterization.
We first determined PIGB expression levels in 37
LCLs selected on the basis of genotypes for those 3
SNPs using both QRT-PCR assay and expression array
data to confirm the association between the SNPs and
PIGB expression. Cells carrying the variant alleles
showed significantly lower expression levels than did
WT cells (Figure 7B). We next determined the functional
impact of these 3 SNPs. As shown in Figure 7C, overex-
pression of a construct for the PIGB coding SNP
Figure 7 (See legend on next page.)
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Figure 7 Functional characterization of SNPs in the PIGB gene. (A) Patterns of linkage disequilibrium (LD) within ~200 Kb surrounding the
rs3797418 SNP among three different ethnic groups using HapMap3 R2 data as a reference. The top 7 SNPs in PIGB are arranged in order from 5′
to 3′, as shown in the gene structure above each plot. Black indicates combinations where R2 = 1 and linkage of disequilibrium (LOD)≥ 2; light
grey, combinations where 0 < R2 < 1 and LOD ≥ 2; white, where R2 = 0 and LOD < 2. (B) Association between SNPs and PIGB expression measured
by QRT-PCR assay and microarray using 37 randomly selected LCLs. (C) Effect of the nonsynonymous coding SNP (rs2290344, M161T) on PIGB
mRNA expression, protein expression and response to gemcitabine. PIGB mRNA and protein levels were determined in SU86 and MDA-MB-231
cells transfected with either PIGB wild-type or variant constructs with GST-tags. Antibody against GST (Antibody #2622, Cell Signaling Inc.) was
used for detection of PIGB expression, and Antibody against MUC1 (VU4H5 Mouse mAb #4538, Cell Signaling Inc.) served as a loading control in
Western Blot assay. Gemcitabine cytotoxicity performed with the MTS assay was performed in cells transfected with WT and variant constructs.
No differences were observed between WT and variant SNP for any of the phenotypes tested. (D) EMSAs were performed for two regulatory SNPs
in PIGB gene. The arrows indicate different binding pattern between WT and variant sequences for rs11636687 and rs28668016.
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did not alter either mRNA or protein levels, nor did it
have an effect on gemcitabine cytotoxicity. We then de-
termined whether the two SNPs in regulatory regions,
rs11636687 and rs28668016, might have functional im-
pact. We performed electrophoresis mobility shift assays
(EMSAs) for these two SNPs to determine whether there
might be differences in binding patterns for possible
transcription factors. Interestingly, the results from
EMSA showed that DNA-protein binding was signifi-
cantly increased for the probe containing the variant
sequences for these two SNPs in both SU86 and MDA-
MB-231 cells (Figure 7D). These results suggested that
these two SNPs might alter the binding of transcription
factors and, as a result, affect PIGB expression level.Discussion
We previously performed a genome wide SNP associ-
ation study with 550 K SNPs obtained with Illumina
HumanHap550 BeadChips for the same cell lines to
identify common polymorphisms that might influence
both gene expression and response to these two drugs
[18]. In the present study, we expanded the number of
SNPs from 550 K to include over 1.3 million SNPs and
selected candidate genes for functional follow-up studies
based on SNP loci. This dense SNP coverage made it
possible to identify many more candidates for functional
follow-ups. That enabled us to take a different approach
by focusing on “SNP loci” instead of single SNPs. The
results listed in Table 3 show that 11 of 26 candidate
genes selected in this fashion were validated functionally,
while only two other genes from the previous 550 k
studies were functionally validated [18].
We also tested the concordance of the results gener-
ated with 550 K and 1.3 million SNPs if we had used the
same strategy as we did in the current study, i.e. using
SNP loci to perform the association studies. The major-
ity of top SNP peaks from the 550 K SNP data for both
drugs displayed less significant SNPs for each locus as
compared to the 1.3 million SNP data (Additional file 1:
Table S3). These observations illustrate the advantage ofthe present selection strategy for candidate identification,
as well as the advantage of using denser SNP coverage.
Of the 26 candidate genes that we identified for
further siRNA screening followed by MTS assay, eleven
candidate genes, including PIGB, TGFBI, DOK6, PSME3,
ZADH2, TUSC3, C14orf169, SMC2, LNX2, RIS1, and
HLA-DRA, showed a significant effect on response to
gemcitabine and/or AraC in SU86 and/or MDA-MB231
cells. To identify potential pathways with which these
genes might be involved, we used a dual luciferase re-
porter gene assay to assess the impact of these genes on
10 major cancer-related signaling pathways. As shown in
Figure 6 and Table 3, except for the SMC2 gene, knock-
down of the other 10 genes in SU86 cells significantly al-
tered activities, based on the luciferase assay for at least
one of the 10 cancer related signaling pathways. Genes
such as TGFB1 showed changes for the most pathways.
While TGFB1 has been well studied, genes such as
C14orf169, an unknown gene, also showed increased
activity in 7 of the 10 pathways.
We also observed that the activities of the Elk-1/SRF,
AP1, NFκB, and Myc/MAX pathways were significantly
decreased in SU86 cells when PIGB was down-regulated
by a specific siRNA. PIGB, a gene of the phos-
phatidylinositol glycan (PIG) class B, encodes an enzyme
involved in the synthesis of a glycosylphosphatidylinosi-
tol (GPI) anchor that is a membrane attachment struc-
ture for many proteins, including membranous enzymes,
receptors, differentiation antigens, and other biologically
active proteins [29]. GPI anchoring is essential for the
expression of many of those proteins in either biological
processes or cancer progression [30,31]. The PIGB pro-
tein is a GPI mannosyltransferase III and is required for
the transfer of the third mannose into the core structure
of the GPI anchor [29,32]. Previous studies have demon-
strated that other PIG class members, such as PIGU and
PIGT, are oncogenes in either human bladder cancer or
breast cancer, respectively [33,34]. Our findings indicate
that PIGB is involved in sensitizing cancer cells to both
gemcitabine and AraC, suggesting a possible role in
oncogenic pathways as well as chemoresistance. The 8
PIGB SNPs were also associated with the expression of
Li et al. BMC Genomics 2014, 15:93 Page 20 of 22
http://www.biomedcentral.com/1471-2164/15/93FKBP5, a gene that we previously reported to be import-
ant for gemcitabine and AraC response [17,27]. Further-
more, PIGB expression itself is also correlated with
FKBP5 gene expression. Although down regulation of
PIGB altered FKBP5 mRNA level, overexpression
of FKBP5 in PIGB stable knockdown cell lines did not
change response to gemcitabine or AraC (Additional file 1:
Figure S3). These observations indicate that PIGB influ-
ences the cytotoxicity of the two cytidine analogues through
mechanisms that differ from FKBP5, in spite of the correl-
ation of their expression levels observed in the LCLs. The
exact mechanisms by which PIGB affects gemcitabine and
AraC cytotoxicity need to be explored in the course of
future experiments.
In addition to the characterization of candidate genes,
we also focused on SNPs in the PIGB gene that showed
cis-regulation of PIGB expression. SNPs in regulatory re-
gions can influence drug response through an influence
on gene expression. During our analysis, we found that
most SNP associations with expression were through
trans-regulation. The reason that we focused on SNPs in
PIGB is because those SNPs displayed cis-regulations of
PIGB and knockdown of PIGB showed an effect on cyto-
toxicity. The EMSA results also demonstrated “shifts”
for the variant SNP sequences (Figure 7D), suggesting
that PIGB gene expression might be regulated through
binding to those transcription factors.
Previous studies demonstrated that one mechanism by
which SNPs might influence drug cytotoxicity is through
transcription regulation in either a cis- or trans-manner
[18,35-37]. In this analysis, we found SNPs that could
both have cis or trans relationship. In addition to the
SNPs that cis regulate PIGB, we also found that SNPs
close to C3orf23 were not only cis-associated with its
own gene expression, but also trans-correlated with the
expression of ZADH2 which was confirmed to affect
drug response of gemcitabine in our functional valid-
ation study. How those genetic variations located in the
upstream of C3orf23 affect the expression of ZADH2
gene in a trans- manner remains unknown. One mech-
anism might be that those SNPs nearby C3orf23 could
alter DNA sequence binding to transcription factors
(TFs), microRNA, or other long non-coding RNA (lnc
RNA), thus affect transcriptional regulation of their tar-
get genes including ZADH2 gene, which could in turn,
affect gemcitabine response.
Conclusions
In summary, this study performed with LCLs followed
by functional characterization has enhanced our under-
standing of the action of gemcitabine and AraC in the
therapy of cancer. Although there are limitations associ-
ated with the use of LCLs [38,39], this system has proven
to be extremely useful, both to generate pharmacogenomichypothesis and to test pharmacogenomic signals identified
during the clinical GWAS [19-21]. Future studies using
patient samples will now be required to confirm the candi-
dates identified during this study.
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Figure S1. Imputation analysis for top SNP loci associated with the
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